Market closed
Sonoma Pharmaceuticals Inc./$SNOA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
Ticker
$SNOA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
10
ISIN
US83558L3033
Website
SNOA Metrics
BasicAdvanced
$5.1M
-
-$3.64
1.43
-
Price and volume
Market cap
$5.1M
Beta
1.43
52-week high
$4.46
52-week low
$1.75
Average daily volume
2.4M
Financial strength
Current ratio
3.343
Quick ratio
2.12
Long term debt to equity
0.595
Total debt to equity
2.444
Management effectiveness
Return on assets (TTM)
-19.72%
Return on equity (TTM)
-64.83%
Valuation
Price to revenue (TTM)
0.233
Price to book
1.05
Price to tangible book (TTM)
1.05
Price to free cash flow (TTM)
25.286
Growth
Revenue change (TTM)
13.51%
Earnings per share change (TTM)
-77.29%
3-year revenue growth (CAGR)
3.82%
3-year earnings per share growth (CAGR)
-57.76%
SNOA News
AllArticlesVideos
Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain
Accesswire·3 weeks ago
Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Sonoma Pharmaceuticals Inc. stock?
Sonoma Pharmaceuticals Inc. (SNOA) has a market cap of $5.1M as of May 14, 2025.
What is the P/E ratio for Sonoma Pharmaceuticals Inc. stock?
The price to earnings (P/E) ratio for Sonoma Pharmaceuticals Inc. (SNOA) stock is 0 as of May 14, 2025.
Does Sonoma Pharmaceuticals Inc. stock pay dividends?
No, Sonoma Pharmaceuticals Inc. (SNOA) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next Sonoma Pharmaceuticals Inc. dividend payment date?
Sonoma Pharmaceuticals Inc. (SNOA) stock does not pay dividends to its shareholders.
What is the beta indicator for Sonoma Pharmaceuticals Inc.?
Sonoma Pharmaceuticals Inc. (SNOA) has a beta rating of 1.43. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.